| Species |
Human |
| Protein Construction |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer [Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and VVVGADGVGK peptide]
Accession # AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGADGVGK |
His |
Avi |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized HLAA*11:01&B2M&KRAS G12D TCR at 2μg/ml (100μl/well) on the plate can bind HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer[Biotin], His & Avi, Human. Test result was comparable to standard batch. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M) |
| Apparent Molecular Weight |
The protein has a predicted MW of 35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
![HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06494 ELISA.jpg&file=scm_files/productFile_notes/2025/04/25/Z06494 ELISA.jpg "HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer[Biotin], His & Avi, Human")
Immobilized HLA-A*11:01&B2M&KRAS G12D TCR at 2 μg/ml (100 μl/well) on the plate. Dose response curve for HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer[Biotin], His & Avi, Human, His Tag with the EC50 of 63.7 ng/ml determined by ELISA.
![HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06494 HPLC.png&file=scm_files/productFile_notes/2025/04/25/Z06494 HPLC.png "HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer[Biotin], His & Avi, Human")
The purity of HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.
![HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06494 PAGE.png&file=scm_files/productFile_notes/2025/04/25/Z06494 PAGE.png "HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer[Biotin], His & Avi, Human")
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
| Target Background |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
| Synonyms |
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
